Our Work in
Antibiotic Research


For more than 80 years, MSD has contributed to the discovery and development of novel medicines and vaccines to combat infectious disease. Today, MSD is a global leader in antimicrobials with a proud heritage, broad portfolio and innovative pipeline.

OUR HISTORY


MSD's Research Laboratories played a central role in the development of antimicrobials


MSD, in collaboration with Rutgers University, developed one of the first methods for mass production of penicillin


MSD markets a number of antibacterial, antifungal, and antiviral products and vaccines for the treatment or prevention of infectious diseases in markets around the globe

MSD IS COMMITTED TO:

Maintaining active R&D programs to address unmet medical needs in the prevention and treatment of infectious disease

Monitoring trends in antibacterial resistance as exemplified by our longstanding commitment to surveillance studies

Supporting responsible use of antimicrobials to help slow development of resistance and preserve current therapeutic options

Advocating for improvements in regulatory guidance and financial incentives to support and accelerate innovation in the development of new antimicrobials, vaccines, services and solutions

FINDING SOLUTIONS TO ANTIMICROBIAL RESISTANCE

There is a critical need for solutions to manage the growing problem of antimicrobial resistance.

INNOVATION

Research and innovation will lead to the development of new antibiotics.

STEWARDSHIP

Antimicrobial stewardship promotes the appropriate use of antimicrobials to reduce resistance.

POLICY

Policies can help spur innovation and regulate the use of antibiotics.



1 The Company Pipeline (May 1, 2019), available at http://www.msd.com/pipeline/MSDPipeline.pdf
2 MSD Corporate News, available at https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-releba

RO-NON-00037
Published February 2020